Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp (IMCC) provides premium medical cannabis products in regulated international markets, with operational hubs in Israel and Germany. This news hub offers investors and industry stakeholders centralized access to official updates and market developments.
Track all corporate announcements including regulatory milestones, strategic partnerships, and operational expansions. Our curated collection ensures timely access to earnings reports, product launches, and compliance achievements that shape this medical cannabis leader's trajectory.
Discover updates on IMCC's EU-GMP certified operations, Focus Medical Herbs collaboration in Israel, and Adjupharm GmbH's German distribution network. Content spans supply chain innovations, licensing agreements, and quality control advancements critical to medical cannabis operations.
Bookmark this page for verified updates from a company maintaining strict adherence to international medical standards. Stay informed about IMCC's data-driven approach to cultivation and distribution in complex regulatory environments.
IM Cannabis (NASDAQ:IMCC), a medical cannabis company operating in Israel and Germany, announced significant changes to its Board of Directors effective September 15, 2025. The company appointed Asaf Yitzhaik and Eli Zamir to replace departing board members Shmulik Arbel and Brian Schinderle.
Oz Adler has been appointed as the new Chairman of the Board, replacing Oren Shuster, who continues as CEO and director. The new board members bring extensive experience in retail, real estate, finance, and capital markets. Additionally, the company announced plans to explore new business opportunities to enhance growth and shareholder value.
IM Cannabis (NASDAQ: IMCC), a medical cannabis company operating in Israel and Germany, has successfully regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq on September 4, 2025 that it now meets the minimum stockholders' equity requirement of $2.5 million under Rule 5550(b)(1). As a result, IMCC's common stock will maintain its listing and continue trading on the Nasdaq Capital Market.
IM Cannabis (NASDAQ: IMCC) has announced key amendments to its November 2024 Warrants and filed a Form F-3 Resale Registration Statement. The company has agreed to reduce the exercise price of the November 2024 Warrants from C$4.32 to C$3.43 and extend their expiration date from November 12, 2026 to July 31, 2030.
The Form F-3 Registration Statement covers 4,982,517 Common Shares, including shares issuable upon exercise of various warrants. The transaction involves participation from company insiders, including CEO Oren Shuster, director Shmulik Arbel, and insider Rafael Gabay, constituting a related party transaction under MI 61-101.
IM Cannabis (NASDAQ: IMCC) reported mixed Q2 2025 financial results, with revenue declining 14% to $12.7 million compared to Q2 2024, primarily due to war-related challenges in Israel and supply chain delays impacting approximately $5 million in revenue.
Despite revenue headwinds, the company demonstrated significant profitability improvements with a 306% increase in gross profit to $3.4 million and gross margin expansion to 27% from 6% year-over-year. The company achieved EBITDA profitability of $0.1 million, compared to a $2.3 million loss in Q2 2024, while maintaining stable operating expenses at $3.8 million.
The quarter saw accelerated growth in Germany of $3.3 million, offset by a $5.3 million decrease in Israel. Cash position stood at $0.8 million as of June 30, 2025, with total assets of $41.1 million and liabilities of $37 million.
IM Cannabis (NASDAQ: IMCC), a medical cannabis company operating in Israel and Germany, has scheduled its Q2 2025 financial results announcement for Tuesday, August 12, 2025, before market opening. The results will cover the period ended June 30, 2025.
IM Cannabis (NASDAQ: IMCC) has successfully closed a private placement offering, raising gross proceeds of approximately US$4.1 million. The company issued 2,050,000 units at C$2.7427 per unit, with each unit comprising one common share (or pre-funded warrant) and one warrant.
The warrants have an exercise price of C$3.43 and a 60-month term. The company plans to use the proceeds for working capital, debt repayment, and general corporate purposes. Pure Equity Ltd. acted as a consultant for the offering.
IM Cannabis has committed to filing a resale registration statement within 30 days of closing, with effectiveness targeted within 60-90 days depending on SEC review.
IM Cannabis (NASDAQ:IMCC), a medical cannabis company operating in Israel and Germany, has filed a shelf registration statement on Form F-3 with the SEC. The registration allows IMCC to offer and sell up to $50 million in securities, including common shares, warrants, units, or combinations thereof.
The shelf registration provides flexibility for future offerings but does not represent an immediate commitment to sell securities. Any potential offerings will be determined based on market conditions, capital needs, and regulatory requirements, with specific terms detailed in future prospectus supplements.
IM Cannabis (NASDAQ:IMCC) has announced two significant developments: a loan agreement with L.I.A. Pure Capital Ltd. and the appointment of Oz Adler to its Board of Directors. The company secured a USD 1 million loan with potential for an additional USD 1 million, bearing 8% annual interest and due by June 30, 2026.
The loan agreement includes specific conditions, including a pledge of IMC Holdings Ltd. shares and a commitment to raise at least USD 3 million through an underwritten offering within 60 days. Mr. Adler, currently CEO of SciSparc Ltd. and an experienced financial executive, joins the board as part of the loan agreement terms, bringing expertise in capital markets, corporate finance, and pharmaceutical ventures.
IM Cannabis (NASDAQ: IMCC), a medical cannabis company operating in Israel and Germany, has provided updates regarding its Nasdaq listing compliance status. The company received a deficiency letter on April 9, 2025, for failing to meet the minimum $2.5 million stockholders' equity requirement for continued Nasdaq listing.
Following submission of its compliance plan on May 23, 2025, Nasdaq has granted IMCC an extension until October 6, 2025, to regain compliance with the listing requirements. The company's shares continue to trade on the Nasdaq Capital Market under "IMCC" while it works to meet the compliance standards.
IM Cannabis (NASDAQ: IMCC) has announced its application for voluntary delisting from the Canadian Securities Exchange (CSE). The company's shares will continue trading on NASDAQ under the symbol "IMCC". The final trading day on CSE is expected to be June 2, 2025.
The decision is driven by several factors: potential transactions that would incur unnecessary costs and delays if listed on CSE, low trading volume on CSE that doesn't justify maintenance expenses, and the aim to create a centralized marketplace on Nasdaq to enhance long-term liquidity and shareholder value.